Psychedelic Treatment Program Launched for Frontline Workers

According to data from Mental Health America, healthcare workers are significantly impacted by the pandemic with reports of 93% experiencing stress, 86% experiencing anxiety and 76% experiencing exhaustion and burnout. Today, a mental health company specializing in psychedelic medicine has bolstered its clinical programming with a group-based psychedelic treatment program now accessible to the public. A Stockhouse Editorial exclusive.

Read the Full Story Here

Top Cannabis News Stories

  1. Top Story: A Canadian biotechnology company completes world’s first ketamine treatment study for a range of behavioral addictions. Stockhouse’s Jon Brown reports.
  2. Delta 9 Cannabis Inc. reports Q1 2022 results.
  3. The Green Organic Dutchman Holdings Ltd. announces raise of additional working capital.
  4. Canopy Growth Corp. to report Q4 and FY 2022 financial results on May 27th.
  5. Cresco Labs Inc. announces “solid quarter” for Q1 2022.

Top Cannabis Stocks | May 12 to May 18, 2022

1. T.HEXO | 17,398 views | HEXO Corp.
2. T.WEED |13,834 views | Canopy Growth Corp.
3. TLRY | 8,410 views | Tilray Brands Inc.
4. C.TNY | 4,629 views | Tinley Beverage Co Inc.
5. T.ACB | 3,443 views | Aurora Cannabis Inc.
6. T.TBP | 3,197 views | Tetra Bio-Pharma Inc.

New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.

For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.

More From The Market Online
Market graph

@ the Bell: Markets hover near all-time highs

A surge in commodity prices helped lift markets trading in Canada’s busiest centre on Friday to nearly reach a new all-time high.

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.